Clinical Trial Update: Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 study evaluating the efficacy and safety of SBI-087 in seropositive patients with active rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• SBI-087

Snippet

Sponsor: Pfizer | Conditions: Active Rheumatoid Arthritis | Phase 2 | Status: COMPLETED